tetano
Editor, Senior Moderator
Int Immunol
. 2021 Sep 7;dxab061.
doi: 10.1093/intimm/dxab061. Online ahead of print.
Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
Kun Xu[SUP] 1 [/SUP], Lianpan Dai[SUP] 1 2 [/SUP], George F Gao[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By May 21 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.
Keywords: SARS-CoV-2; T cell; antibody; variant.
. 2021 Sep 7;dxab061.
doi: 10.1093/intimm/dxab061. Online ahead of print.
Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
Kun Xu[SUP] 1 [/SUP], Lianpan Dai[SUP] 1 2 [/SUP], George F Gao[SUP] 2 [/SUP]
Affiliations
- PMID: 34491327
- DOI: 10.1093/intimm/dxab061
Abstract
Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By May 21 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.
Keywords: SARS-CoV-2; T cell; antibody; variant.